Fact CheckerSign in

NCT07864792Not yet recruiting

Transcranial Direct Current Stimulation to Improve Gait for Breast Cancer Survivor's Who Received Taxene and/or Platinum Chemotherapy

A Randomized, Sham Controlled, Double Blinded, Crossover Mechanistic Trial of the Impact of Transcranial Direct Current to the Left Dorsolateral Prefrontal Cortex on Gait in Older Breast Cancer Survivor's Post-Taxane Chemotherapy

Source: ClinicalTrials.gov · Last updated 8 Oct 2026

Brief summary (registry, in English)

This clinical trial tests the effect of transcranial direct current stimulation (tDCS) to improve gait in older breast cancer survivors who received taxane and/or platinum chemotherapy. Chemotherapy, especially taxane or platinum therapy, can cause damage to the to the nerves resulting in numbness, tingling and pain, which can cause difficulty walking. It can also cause cognitive dysfunction which may effect gait. TDCS is a non-invasive brain stimulation device which uses a very mild electrical current applied to the scalp to temporarily stimulate a specific area of the brain involved in thinking and movement which may improve walking, particularly while doing two things at once. TDCS may be effective in improving gait for older breast cancer survivors who received taxane and/or platinum chemotherapy.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
60 (estimated)
First submitted
2 Oct 2026
Start date
1 Sept 2026
Primary completion date
30 Sept 2029
Lead sponsor
University of Michigan Rogel Cancer Center
NCT number
NCT07864792

What you commit to

  • Study type: Interventional
  • Planned participants: 60
  • From 1 Sept 2026 to the primary completion date, 30 Sept 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder
  • Active neurotoxic chemotherapy (taxane, platinum or vinca alkaloid) or radiation therapy

Other illness

  • Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance
  • Any unstable medical condition
  • Myocardial infarction within the past six months
  • History of immune check point inhibitor therapy
  • Any history of brain or cervical spine surgery, known hearing, visual, or vestibular impairment
  • Contraindications to transcranial direct simulation (tDCS), including reported seizure within the past two years,, metal objects in head or neck, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp

Other

  • Chronic vertigo

Who the study is looking for

  • Women aged 60-85 years
  • Breast cancer survivors, stages I-IV without clinical suspicion or evidence of brain metastasis
  • Completion of last taxane and/or platinum chemotherapy treatment ≥ 6 months prior, but chemotherapy was received after the age of 60. Taxane combined with a history of platinum, anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy, Anti-HER2, and CDK 4/6 inhibitors are permitted
  • Ability to walk unassisted for 60 seconds
  • Proficient in English
  • Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD)
  • No history of a second cancer besides skin cancer

Age in the registry: 60 years to 85 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University of Michigan Rogel Cancer Center
Coordinator of this site? Confirm its status
Ann ArborUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.